Institut za tržišna istraživanja AD Beograd
Institut za tržišna istraživanja AD Beograd
05/07/2024 | Press release | Distributed by Public on 05/07/2024 03:36
Clinical Efficacy Endpoints from the Phase 3 CANOPY Study Evaluating[...]
Pharmacokinetics and Serum Virus Neutralizing Antibody Titers Following[...]
Results from a Phase 1 First in human Study of Pemivibart: an[...]
Institut za tržišna istraživanja AD Beograd
05/07/2024 | Press release | Distributed by Public on 05/07/2024 03:36
Please select the service you want to use:
Smartlinks | Institut za tržišna istraživanja AD Beograd | Finance | Security Markets | Security Markets | Company News | Shareholders | Shareholder Meeting | Market Research | Arts and Culture | Entertainment | Media | Securities Issuers | Market Research and Polling Companies | Belgrade Stock Exchange
Copyright ©2006-2024 Public Technologies Inc. | Privacy Policy | Terms of Use | Contact